TSG101: A Novel Anti-HIV-1 Drug Target

被引：30
作者：
Chen, Hongfei [1 ]
Liu, Xinyong [1 ]
Li, Zhenyu [1 ]
Zhan, Peng [1 ]
De Clercq, Erik [2 ]
机构：
[1] Shandong Univ, Sch Pharmaceut Sci, Dept Med Chem, Jinan 250012, Shandong, Peoples R China
[2] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
来源：
CURRENT MEDICINAL CHEMISTRY | 2010年 / 17卷 / 08期
基金：
中国国家自然科学基金;
关键词：
TSG101; HIV-1; UEV; PTAP; budding; inhibitors; peptoid; cyclic peptide; EXPEDITED LIBRARY SYNTHESIS; UEV DOMAIN; ESCRT-I; CELLULAR-PROTEINS; HOST PROTEINS; HIV-1; P6; COMPLEX; IDENTIFICATION; EXPRESSION; MACHINERY;
D O I：
10.2174/092986710790514444
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The life cycle of HIV-1 requires extensive assistance from the host cell proteins and pathways. TSG101 is one of the cellular proteins involved in the budding process of HIV-1, and plays an important role in the cellular vacuolar protein sorting (Vps) pathway. Its main function being recognizing ubiquitinated cargo, TSG101 also proved to be essential for the budding process of HIV-1 virions. In this process, TSG101 is recruited from internal site of the infected cell to the budding site to aid in the release of the HIV-1 virus particles. Depletion of TSG101 from virus-producing cells can lead to a budding defect. Therefore, TSG101 is a potentially new attractive target for therapeutic intervention in AIDS. This review describes the structure and function of TSG101 and latest progress in the discovery of TSG101-directed HIV-1 inhibitors.
引用
收藏
页码：750 / 758
页数：9
相关论文
共 46 条
[1]   The molecular basis of HIV capsid assembly - five years of progress [J].
Adamson, CS ;
Jones, IM .
REVIEWS IN MEDICAL VIROLOGY, 2004, 14 (02) :107-121
[2]   Endosome-associated complex, ESCRT-II, recruits transport machinery for protein sorting at the multivesicular body [J].
Babst, M ;
Katzmann, DJ ;
Snyder, WB ;
Wendland, B ;
Emr, SD .
DEVELOPMENTAL CELL, 2002, 3 (02) :283-289
[3]   Late budding domains and host proteins in enveloped virus release [J].
Bieniasz, PD .
VIROLOGY, 2006, 344 (01) :55-63
[4]   HIV disease treatment in the era of HAART [J].
Bonfanti, P ;
Capetti, A ;
Rizzardini, G .
BIOMEDICINE & PHARMACOTHERAPY, 1999, 53 (02) :93-105
[5]  
Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725
[6]   HIV-1 assembly and maturation - Brief review [J].
Bukrinskaya, AG .
ARCHIVES OF VIROLOGY, 2004, 149 (06) :1067-1082
[7]   Tsg101: HIV-1's ticket to ride [J].
Carter, CA .
TRENDS IN MICROBIOLOGY, 2002, 10 (05) :203-205
[8]   The design of drugs for HIV and HCV [J].
De Clercq, Erik .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) :1001-1018
[9]   Retrovirus budding [J].
Demirov, DG ;
Freed, EO .
VIRUS RESEARCH, 2004, 106 (02) :87-102
[10]   Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs:: implications for the development of therapeutic strategies [J].
Demonté, D ;
Quivy, V ;
Colette, Y ;
Van Lint, C .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (06) :1231-1238
12345